Trispecific antibodies: is more always better? Advances and boundaries

Xun Liao; Wenjie Hou; Junxiu Zhou; Liang Feng; Rui Ma; Yong Peng

doi:10.1093/pcmedi/pbag015

Precision Clinical Medicine ›› 2026, Vol. 9 ›› Issue (2) :pbag015 DOI: 10.1093/pcmedi/pbag015

OPINION

research-article

Trispecific antibodies: is more always better? Advances and boundaries

Author information +

History +

PDF (538KB)

Cite this article

Download citation ▾

Xun Liao, Wenjie Hou, Junxiu Zhou, Liang Feng, Rui Ma, Yong Peng. Trispecific antibodies: is more always better? Advances and boundaries. Precision Clinical Medicine, 2026, 9 (2) : pbag015 DOI:10.1093/pcmedi/pbag015

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Zhao L, Li S, Wei X et al. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood 2022; 140:1790-802. https://doi.org/10.1182/blood.2022016243

[2]

Lau D, Repenning P, Hernaez DC et al. Abstract 7318: ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer. Cancer Res 2025; 85:7318. https://doi.org/10.1158/1538-7445.AM2025-7318

[3]	Zhang K, Liu B, Yang L et al. Abstract 2125: The trispecific T cell engager platform enhances T cell function and therapeutic efficacy via integrated 4-1BB nanobody co-stimulation. Cancer Res 2025; 85:2125. https://doi.org/10.1158/1538-7445.AM2025-2125

[4]	Austin RJ, Lemon BD, Aaron WH et al. TriTACs, a novel class of T-cell-engaging protein constructs designed for the treatment of solid tumors. Mol Cancer Ther 2021; 20:109-20. https://doi.org/10.1158/1535-7163.MCT-20-0061

[5]	Yang C, Wang P, Yang M et al. A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity. Cell Rep Med 2025; 6:102409. https://doi.org/10.1016/j.xcrm.2025.102409

[6]	Lee J, Tang H, Yu J et al. Abstract 6068: CT111, a novel trispecific PD-1 x CTLA-4 x VEGF single-domain antibody, synergistically targets exhausted T cells and promotes cooperative antitumor effects. Cancer Res 2025; 85:6068. https://doi.org/10.1158/1538-7445.AM2025-6068

[7]	Lemech C, Coward J, Gao B et al. 1545P CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: An open-label, multicenter, phase I firstin-human study. Ann Oncol 2025; 36:S859-60. https://doi.org/10.1016/j.annonc.2025.08.2176

[8]	Yang C, Guo S, Ye K et al. A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity. Nat Biomed Eng 2026; 10:732-52 https://doi.org/10.1038/s41551-025-01569-4

[9]	Huang Y, Zhang R, Zhang X et al. Abstract 3513: CC312, a trispecific CD19-targeting co-stimulatory T cell engager, for the treatment of B cell malignancies and autoimmune diseases. Cancer Res 2025; 85:3513. https://doi.org/10.1158/1538-7445.AM2025-3513

[10]	Zhao X, Jing W, Wang G et al. A logic-gated trispecific engager enhances macrophage killing of cancer cells in solid tumors. Nat Biotechnol 2026. https://doi.org/10.1038/s41587-026-03057-9